We are live on ! Find out more
ONC icon

BeOne Medicines

264 hedge funds and large institutions have $15B invested in BeOne Medicines in 2021 Q4 according to their latest regulatory filings, with 46 funds opening new positions, 85 increasing their positions, 91 reducing their positions, and 34 closing their positions.

New
Increased
Maintained
Reduced
Closed

35% more first-time investments, than exits

New positions opened: 46 | Existing positions closed: 34

9% more funds holding in top 10

Funds holding in top 10: 11 → 12 (+1)

4% more funds holding

Funds holding: 255 → 264 (+9)

0.92% less ownership

Funds ownership: 55.12% → 54.2% (-0.92%)

7% less repeat investments, than reductions

Existing positions increased: 85 | Existing positions reduced: 91

51% less capital inflows, than outflows

Capital inflows: $300M | Capital outflows: $615M

77% less call options, than puts

Call options by funds: $28.3M | Put options by funds: $125M

Holders
264
Holders Change
+9
Holders Change %
+3.53%
% of All Funds
4.05%
Holding in Top 10
12
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+9.09%
% of All Funds
0.18%
New
46
Increased
85
Reduced
91
Closed
34
Calls
$28.3​M
Puts
$125​M
Net Calls
-⁠$96.4​M
Net Calls Change
-⁠$81.7​M

ONC Hedge Fund Activity: Q4 2021 in Review

264 of the 6,524 institutional investors tracked by Wall St. Rank reported a position in BeOne Medicines (ONC) for Q4 2021, worth a combined $15B — down 26% from $20.4B a quarter earlier.

Buyers outnumbered sellers: 46 funds opened new ONC positions and 34 closed out — a net gain of 12 holders — while 85 added to existing stakes and 91 trimmed.

The largest buyer was Indus Capital Partners, adding an estimated $30.4M. The largest seller was Boxer Capital, cutting an estimated $89.2M.

  • 264 institutional investors held BeOne Medicines (ONC) as of Q4 2021, up from 255 in Q3 2021.
  • Funds reported $15B of BeOne Medicines stock for Q4 2021, down 26% quarter-over-quarter.
  • 46 funds opened new BeOne Medicines positions in Q4 2021 and 34 closed out, a net change of +12 holders.
  • The largest BeOne Medicines buyer in Q4 2021 was Indus Capital Partners, an estimated $30.4M added.
  • The largest BeOne Medicines seller in Q4 2021 was Boxer Capital, an estimated $89.2M sold.

Based on aggregated 13F filings for Q4 2021.